Glenmark Life Sciences Company Description

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.

The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin.

It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.

The company’s APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives.

It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India.

Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.

Glenmark Life Sciences Limited

Country	India
Founded	2011
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	2,014
CEO	Yasir Rawjee

Contact Details

Address: OIA House Mumbai, Maharashtra 400099 India
Phone	91 22 6829 7979
Website	glenmarklifesciences.com

Stock Details

Ticker Symbol	GLS
Exchange	National Stock Exchange of India
Fiscal Year	April - March
Reporting Currency	INR
ISIN Number	INE03Q201024
SIC Code	2833

Key Executives

Name	Position
Dr. Yasir Yusufali Rawjee Ph.D.	Chief Executive Officer, MD and Director
Tushar P. Mistry	Senior Vice President and Chief Financial Officer
Vinod Naik	Group Vice President, Head of Technical Operations and Whole Time Director
Rudalf Corriea	Company Secretary and Compliance Officer
Soumi Rao	General Manager of Corporate Communications
Sumantra Mitra	Senior Vice President and Head of Human Resources
Mathew George	Senior Vice President and Head of Regulatory Affairs
Navin Kumar Agrawal	Vice President and Head of Corporate Quality